Clinical trial
Phase IIA Study to Evaluate the Efficacy of HIF2a Inhibitor Belzutifan in Patients With Erythrocytosis by EPAS1 (HIF2a), EGLN1 (PHD2), or VHL Mutations
NCT07895966 is registered in ClinicalTrials.gov with University of Utah as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase IIA Study to Evaluate the Efficacy of HIF2a Inhibitor Belzutifan in Patients With Erythrocytosis by EPAS1 (HIF2a), EGLN1 (PHD2), or VHL Mutations
- Lead sponsor
- University of Utah
- Phase
- Phase 2
- Overall status
- Not yet recruiting
- Start date
- October 1, 2026
- Completion date
- September 30, 2028
- Enrollment
- 16 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
erythrocytosis, pulmonary hypertension, thrombosis
Arms
As registered; 1 arm.
-
Belzutifan Treatment
Primary endpoints
Registered primary outcome measures; 1 primary.
-
Normalization of hemoglobin
Either normalizing Hb or lowering of patient Hb by at least 1.5g/dL from the patient's baseline by 12 weeks of therapy.
Lead sponsor's other trials
University of Utah, most recent start first.
+990 more trials See the organization page
Similar trials
Same condition (Polycythemia) and phase, most recent start first.